Acute Lower Limb Ischaemia
Acute limb ischaemia (ALI) is a sudden reduction in arterial perfusion, usually with symptoms for less than two weeks. Grade the limb before choosing the treatment. Sensory loss and especially new weakness identify a threatened limb. Give heparin unless contraindicated, resuscitate and arrange timely reperfusion: prompt for IIa, immediate for IIb. An established irreversible limb should not be revascularised. Treatment must address the obstruction, reperfusion injury and the cause of the event. [1–3]
Written August 15, 2026 · Mr Razhan K Ali
1 · UNDERSTAND
Why the presentation varies
An embolus may abruptly obstruct a previously well-perfused limb with few collaterals. Thrombosis on established peripheral arterial disease (PAD) may progress less dramatically because collaterals already exist. Neither pattern is diagnostic: embolism and atherosclerosis often coexist. [2,3]
| Likely cause | Useful clues | Treatment implication |
|---|---|---|
| Embolus | Abrupt onset; AF or another cardiac source; preserved contralateral pulses | Remove the embolus and investigate its source. |
| Native-artery thrombosis | Previous claudication, diffuse PAD, contralateral pulse loss | Clear thrombus and treat the underlying lesion. |
| Graft or stent occlusion | Previous reconstruction; technical failure, stenosis or disease progression | Identify why it failed; clot removal alone may not be durable. |
| Thrombosed popliteal aneurysm | Aneurysm history or popliteal mass; distal embolisation and poor tibial run-off | Restore distal perfusion and plan definitive aneurysm repair together. |
These are clinical clues, not exclusion criteria. Consider dissection, trauma, low-flow states and acquired prothrombotic disease when the presentation is atypical. Bilateral ischaemia with absent femoral pulses suggests acute aortic occlusion and a potentially large systemic reperfusion burden. [1–3]
Grade viability at the bedside
Record onset and progression, rest pain, skin changes, sensation, active ankle/toe movement and arterial/venous Doppler signals. Examine both limbs and femoral pulses, and assess the patient's cardiovascular state. Do not wait for all six Ps. [1–3]
| Rutherford grade | Sensation | Motor function | Arterial / venous Doppler | Implication |
|---|---|---|---|---|
| I — viable | Normal | Normal | Audible / audible | No immediate threat; urgent assessment and serial examination. |
| IIa — marginally threatened | None or minimal loss, usually toes | No weakness | Usually inaudible / audible | Salvageable with prompt treatment. |
| IIb — immediately threatened | Loss beyond toes, usually with rest pain | Mild–moderate weakness | Inaudible / audible | Immediate revascularisation. |
| III — irreversible | Profound anaesthesia | Profound paralysis; rigor may occur | Inaudible / inaudible | Major tissue loss or permanent nerve damage inevitable. |
Typical findings are shown; use the whole examination and repeat it. Arterial signals may persist in IIa, and rigor is not essential for III. Fixed non-blanching mottling and muscle rigidity support irreversible injury, but no isolated sign or elapsed-time threshold establishes viability. [1,2]
Investigate without delaying treatment
CTA is the preferred anatomical study when imaging will not delay treatment. Assess inflow, the occlusion, distal run-off and previous reconstructions. Immediately available duplex may suffice; catheter angiography can lead directly to treatment. [1,3]
Send FBC/platelets, renal function, electrolytes, coagulation and group-and-save/crossmatch as appropriate; obtain an ECG. Blood gas and CK help assess systemic injury. Do not use CK, myoglobin or an ABI threshold to decide between revascularisation and amputation, or wait for blood results before treating a threatened limb. [1–3]
2 · DECIDE
Act in parallel
Involve the vascular consultant +/- IR team and anaesthetist; arrange urgent transfer when the required treatment is unavailable. Give IV unfractionated heparin (UFH), unless contraindicated: 5,000 IU or 70–100 IU/kg, followed by an infusion adjusted to local monitoring. Check existing anticoagulation, bleeding and heparin-induced thrombocytopenia (HIT); suspected HIT requires specialist-guided non-heparin anticoagulation. Suspected dissection or bleeding trauma needs an individual anticoagulation decision. [1,4,5]
Provide analgesia and correct dehydration without overlooking cardiac or renal failure. Monitor physiology and urine output in severe ischaemia, and plan for reperfusion-related hyperkalaemia, acidosis and critical-care needs before restoring flow. [1–3]
ESVS recommends supplemental oxygen while awaiting revascularisation. BTS uses prescribed targets, usually 94–98%, or 88–92% initially in patients at risk of hypercapnic respiratory failure pending blood gases. Critical illness warrants immediate oxygen during resuscitation, followed by titration; a stable patient already within target does not need indiscriminate oxygen. [1,7]
Match the strategy to limb threat
I: investigate the cause and reassess. ESVS favours initial conservative treatment for stable, non-threatening acute-onset claudication and advises against catheter-directed thrombolysis (CDT) in that group. This is not a rule to leave every viable acute occlusion untreated. ACC/AHA 2024 recommends revascularisation for salvageable ALI, including category I; document the decision according to symptoms, cause, anatomy and progression. [1,3,5]
IIa: obtain urgent anatomical assessment and plan prompt revascularisation. CDT is a recommended alternative to surgery, not a compulsory first treatment; thrombectomy, bypass or hybrid treatment may be more suitable. [1]
IIb: use the fastest suitable open, endovascular or hybrid route to reperfusion. Do not delay for imaging or prolonged lysis. ESVS permits CDT in selected IIb cases when started promptly, often with aspiration or thrombectomy, provided the strategy meets the limb's urgency. [1–3]
III: do not revascularise an established irreversible limb. Resuscitate and decide between primary amputation and palliation. If IIb versus III is uncertain, obtain immediate senior reassessment: recent weakness may still be reversible. [1–3]
Baseline function, frailty, physiological reserve and the patient's goals modify these decisions; age or cancer alone does not exclude limb salvage. [1,3]
UK timing: NCEPOD supports direct vascular-hub access for severe ALI with new sensory/motor impairment and describes treatment of IIb within six hours of symptom onset. This is a service target—not a safe waiting period or a test of irreversibility. Act immediately when IIb is recognised. [6]
Choose a method that treats the cause
A surgically accessible embolus in a relatively normal artery may be treated by balloon thrombo-embolectomy. Thrombosis on PAD or a failed reconstruction often needs additional angioplasty, endarterectomy or bypass. Vein is generally preferred for infrainguinal bypass, but urgency and available conduit matter. [1–3]
For a thrombosed popliteal aneurysm, consider vein bypass and restoration of tibial run-off. Pre- or intra-operative lysis may improve distal targets; do not postpone IIb reperfusion for prolonged lysis. Stent grafting is not ESVS's first-line treatment for aneurysm-related ALI. [1,3]
3 · JUSTIFY
Limb threat determines the available time; anatomy, cause and physiology determine the method. Mechanical clot removal can restore flow quickly. CDT can clear thrombus in smaller distal vessels but takes time and exposes the patient to bleeding. Either may need adjunctive treatment of the underlying lesion. [1–3,13]
| Evidence | What changes the decision |
|---|---|
| STILE, 1994 | Included non-embolic native-artery and graft occlusion, including longer-duration disease. The overall early composite favoured surgery, whereas the acute subgroup had better six-month amputation-free survival with lysis. Early stopping, catheter-placement failures and subgroup interpretation prevent a universal lysis-first conclusion. [8] |
| TOPAS, 1998 | In 544 patients with occlusion for ≤14 days, six-month amputation-free survival was 71.8% with urokinase versus 74.8% with surgery, without a significant difference. Major bleeding was 12.5% versus 5.5%. These findings do not prove equivalence of modern strategies. [9] |
| Cochrane, 2018 | Five RCTs involving 1,292 patients showed no clear difference in limb salvage, amputation or death, but more major bleeding and distal embolisation with thrombolysis. The evidence was generally low quality. [10] |
Modern thrombectomy evidence remains limited. A 50-patient Rotarex-versus-CDT trial in thrombotic ALI without motor deficit found no statistically significant difference in technical success or amputation; it does not establish superiority or applicability to IIb with weakness. A 2026 review of 24 observational studies reported low/very-low-certainty evidence for rotational thrombectomy, usually with adjuncts—not the isolated device effect or comparative superiority. Its search ended before the small RCT was published. [11,12]
Ongoing trial — ESTABLISH: This UK multicentre randomised trial compares open surgical and endovascular revascularisation strategies for acute lower limb ischaemia, with six-month amputation-free survival as its primary outcome. The trial registry lists it as ongoing and recruiting (checked 2 October 2026). [17]
4 · PERFORM
Prepare for treatment and rescue
Discuss the intended benefit, reasonable alternatives, likely function and material risks: death, limb loss, bleeding, intracranial haemorrhage with lysis, renal failure, compartment syndrome, fasciotomy and further intervention. Agree the fallback plan if initial treatment fails. [1–3]
Use an environment with open and endovascular capability where possible. Consider wire-guided embolectomy under fluoroscopy; never force a catheter against resistance. An anaesthetist should be present even during embolectomy under local anaesthesia. [1,3]
Confirm more than clot retrieval
ESVS recommends completion angiography after open or endovascular revascularisation. Check inflow, residual thrombus, the culprit lesion and distal run-off, and correct important residual disease. Backbleeding alone does not prove clearance. Document the final clinical, neurological and Doppler findings. [1–3]
Guidance difference: CIRSE's September 2026 Standards of Practice favours selective angiography after surgical embolectomy. It is not a replacement ESVS guideline; this article retains the ESVS completion-imaging recommendation. [1,15]
CDT: selection and safety
Confirm that the limb can tolerate the treatment time and assess bleeding risk before starting. The following is the ESVS contraindication framework; also apply the current local drug protocol. [1]
| Category | Contraindications |
|---|---|
| Absolute | Stroke/TIA within 2 months; active bleeding diathesis; gastrointestinal bleeding <10 days; intracranial/spinal surgery within 3 months; intracranial trauma within 3 months. |
| Relative — major | CPR within 10 days; major non-vascular surgery or trauma within 10 days; uncontrolled systolic BP >180 or diastolic BP >110 mmHg; non-compressible vessel puncture; intracranial tumour; recent eye surgery. |
| Relative — minor | Hepatic failure, particularly with coagulopathy; bacterial endocarditis; pregnancy; diabetic haemorrhagic retinopathy. |
Use ultrasound-guided access and a locally agreed intra-arterial rtPA/urokinase regimen. Systemic IV thrombolysis is not recommended. During CDT, ESVS advises against continuous systemic therapeutic UFH and routine fibrinogen monitoring. Low-dose sheath-patency heparin is a separate protocol decision; clinical and laboratory safety monitoring remains necessary. [1,13]
Monitor the limb, vital signs, access site and bleeding closely. Major bleeding requires cessation of lysis, resuscitation and urgent investigation; new neurological symptoms require urgent exclusion of intracranial haemorrhage. Clinical deterioration demands immediate reassessment and rescue, not waiting for the next angiogram. Reconsider the strategy if angiography shows no improvement over 6–12 hours, even with a stable limb. [1,3]
5 · MANAGE
Anticipate reperfusion injury
Reperfused muscle releases potassium, acid and myoglobin; capillary leakage causes swelling within fixed fascial compartments. The consequences may be systemic—arrhythmia, shock and renal injury—or local, with compartment pressure compromising tissue perfusion despite a patent artery. [2,3,14]
Monitor haemodynamics, urine output, electrolytes, renal function and blood gas/CK as indicated. Treat hyperkalaemia promptly, guide fluids by physiology and involve critical care/renal services when needed. Persistent or recurrent ischaemia requires urgent reassessment for residual clot, re-occlusion or untreated inflow/outflow disease. [1–3]
Recognise and decompress compartment syndrome
Look for escalating pain or analgesic requirement, tense swelling, pain on passive stretch and new neurological deficit. Pain may be muted by nerve injury or analgesia. Restored pulses do not exclude compartment syndrome. Measure pressures when the diagnosis is uncertain, without delaying decompression of an established syndrome. [1–3,14]
Established post-ischaemic compartment syndrome requires emergency four-compartment fasciotomy. ESVS advises intervention as soon as possible and within two hours of diagnosis. Ensure the deep posterior compartment is actually released; opening the superficial posterior compartment alone is insufficient. Leave wounds open for reassessment, debridement when needed and later closure. [1,3,14]
Consider prophylactic fasciotomy after profound or prolonged ischaemia, including after endovascular reperfusion; do not perform it routinely in every ALI patient. [1]
Prevent recurrence according to the cause
Embolic ALI: investigate with ECG, appropriate rhythm monitoring and echocardiography; examine the aorta when no cardiac source is found. Do not delay limb treatment for this work-up. AF- or intracardiac-thrombus-related embolism warrants long-term therapeutic anticoagulation. For embolism without an identified source, anticoagulation is an individual decision, not an automatic lifelong prescription. [1,4]
Atherosclerotic thrombosis: use a statin, smoking cessation and cardiovascular risk management. Select antithrombotic therapy according to the reconstruction, bleeding risk and other indications; full-dose anticoagulation is not routine PAD treatment. After lower-limb revascularisation for atherosclerotic disease, consider aspirin 75–100 mg daily plus rivaroxaban 2.5 mg twice daily when bleeding risk is not high, applying NICE eligibility in the UK. This is PAD secondary-prevention evidence, not proof of an ALI-specific regimen, and the vascular rivaroxaban dose does not treat AF. [1,4,16]
Do not routinely add antiplatelet therapy to full-dose anticoagulation. Any additional treatment for a recent intervention or selected graft-patency indication needs a documented rationale, duration and review date. Unexplained or recurrent thrombosis may warrant targeted haematology assessment rather than indiscriminate acute-phase thrombophilia testing. [4]
Follow function as well as patency
Arrange clinical and reconstruction-specific surveillance before discharge, including duplex where appropriate. New symptoms, loss of pulses or a significant ABI fall warrant prompt reassessment and imaging. After popliteal aneurysm repair, assess the graft and excluded sac and screen for aneurysms elsewhere. [1]
Address wounds, mobility, rehabilitation and cardiovascular health. Give clear instructions to seek urgent care for recurrent pain, coldness, numbness or weakness. Limb salvage without useful function is not the only outcome that matters; amputation or palliation still requires active symptom control and support. [1,3]
6 · REMEMBER — What must I retain?
If you remember only 10 things
-
Assess viability now, then reassess. The six Ps are prompts, not a checklist that must be complete.
-
Give UFH unless contraindicated; resuscitate and plan treatment in parallel.
-
A viable limb still needs urgent assessment. ESVS's conservative option concerns stable non-threatening acute claudication.
-
IIa needs prompt treatment; CDT is an alternative to surgery.
-
IIb needs immediate flow restoration by the quickest appropriate method.
-
Do not revascularise a confirmed irreversible limb.
-
Imaging must help treatment, not delay it.
-
Confirm clearance and treat the culprit lesion, not just the clot.
-
Anticipate reperfusion injury and decompress established compartment syndrome urgently.
-
Secondary prevention follows the cause and intervention; antiplatelet therapy and therapeutic anticoagulation are not interchangeable. [1,2,3]
Key numbers in context
-
Less than 2 weeks: usual ALI definition, not a deadline after which urgency disappears.
-
5,000 IU or 70–100 IU/kg: initial IV UFH options, subject to contraindications and local protocol.
-
Within 2 hours of diagnosis: ESVS fasciotomy timing; act as soon as possible.
-
6 hours from symptoms: NCEPOD's severe-ALI pathway target, not a safe delay or an amputation rule. [1,5]
Memory hook: Grade the limb. Restore flow in time. Watch reperfusion. Treat the cause.
Related procedure: Transfemoral (above-knee) amputation.
References
- Björck M, Earnshaw JJ, Acosta S, et al. Editor's Choice—European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. Eur J Vasc Endovasc Surg. 2020;59:173–218. doi:10.1016/j.ejvs.2019.09.006.
- Sidawy AN, Perler BA, editors. Rutherford's Vascular Surgery and Endovascular Therapy. 10th ed. Elsevier; 2023.
- Loftus I, Hinchliffe RJ, editors. Vascular and Endovascular Surgery: A Companion to Specialist Surgical Practice. 7th ed. Elsevier; 2024.
- Twine CP, Kakkos SK, Aboyans V, et al. Editor's Choice—European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. Eur J Vasc Endovasc Surg. 2023;65:627–689. doi:10.1016/j.ejvs.2023.03.042.
- Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA multisociety guideline for the management of lower extremity peripheral artery disease. Circulation. 2024;149:e1313–e1410. doi:10.1161/CIR.0000000000001251.
- NCEPOD. Risking Life and Limb: A review of the quality of care provided to adults with acute limb ischaemia. 2025. Report and recommendations.
- O'Driscoll BR, Howard LS, Earis J, Mak V. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017;72(Suppl 1):ii1–ii90. doi:10.1136/thoraxjnl-2016-209729. Published recommendation summary.
- The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. Ann Surg. 1994;220:251–266; discussion 266–268. Primary report. doi:10.1097/00000658-199409000-00003.
- Ouriel K, Veith FJ, Sasahara AA; TOPAS Investigators. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med. 1998;338:1105–1111. Primary report. doi:10.1056/NEJM199804163381603.
- Darwood R, Berridge DC, Kessel DO, Robertson I, Forster R. Surgery versus thrombolysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev. 2018;8:CD002784. doi:10.1002/14651858.CD002784.pub3.
- Elkerdawi SO, Abdelbary MS, Rizk MA, Ibrahim H, El-Awady K. Randomized prospective comparative study of mechanical thrombectomy by Rotarex device versus catheter-directed thrombolysis in the management of acute thrombotic lower limb ischemia without motor deficit. J Endovasc Ther. 2026;33:2129–2138. Epub 28 August 2025. doi:10.1177/15266028251363509.
- Stanberry B, Deloose K, Gouëffic Y, et al. Rotational percutaneous mechanical thrombectomy for acute and subacute limb ischaemia: a systematic review and proportional meta-analysis. J Endovasc Ther. Published online 11 August 2026. doi:10.1177/15266028261467201.
- Schneider PA. Endovascular Skills: Guidewire and Catheter Skills for Endovascular Surgery. 4th ed. CRC Press; 2020.
- Chaikof EL, Cambria RP, editors. Atlas of Vascular Surgery and Endovascular Therapy: Anatomy and Technique. Saunders; 2014.
- Hamady M, Wolf F, Al-Rekabi A, Katsanos K, Perkov D, Ruffino MA. CIRSE Standards of Practice for the Endovascular Management of Acute Lower Limb Ischaemia. Cardiovasc Intervent Radiol. Published online 29 September 2026. doi:10.1007/s00270-026-04622-0.
- NICE. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease. TA607. 2019. Guidance.
- ESTABLISH. Endovascular strategy versus Surgical strategy for the Treatment of Acute Limb Ischaemia of the lower limb. ISRCTN15236323; investigator study page. Registry record last updated 26 August 2026; checked 2 October 2026. doi:10.1186/ISRCTN15236323.